People aged 75 and over will be eligible to receive a COVID-19 vaccine in France starting Monday.

Up until now, only residents of nursing homes and medical staff aged 50 and over were able to be vaccinated against the disease.

France is also expanding its vaccination campaign to include anyone with high-risk conditions, such as cancer patients undergoing chemotherapy or transplant patients.

The move comes after the country's death toll from COVID-19 topped 70,000 over the weekend.

France has confirmed more than 2.9 million cases of COVID-19 since the start of the pandemic, including at least 70,283 deaths, according to the latest data from the country's public health agency. The Western European nation has the sixth-highest tally of diagnosed cases in the world, after the United States, India, Brazil, Russia and the United Kingdom, according to a real-time count kept by Johns Hopkins University.

So far, the European Medicines Agency has approved two COVID-19 vaccines for use in the European Union -- one developed by U.S. pharmaceutical giant Pfizer and its German partner BioNTech, and another developed by American biotechnology company Moderna.

ABC News' Ibtissem Guenfoud contributed to this report.

A public school district in Oklahoma City canceled basketball games on Friday night after witnessing what it called a "super-spreader event."

Millwood Public Schools said it "made the decision to put kids and families first," pulling its basketball players off the court during games against Community Christian School in Norman, about 20 miles south of downtown Oklahoma City. The school district posted photos on Facebook showing a crowded gymnasium with few people wearing masks or maintaining distances.

"We will NOT subject our kids and families to a super-spreader event just to compete," Millwood Public Schools wrote in the Facebook post Friday night.

Community Christian School's athletics director, Mat McIntosh, told Oklahoma City ABC affiliate KOCO-TV that the photos shared on social media showed the home side, which "was three-fourths full." He said that they "would never put any students at risk."

"During [Friday] night’s game when the decision was made to pull the players off the court, we were caught off guard," McIntosh said in a statement. "We hated that. It has been our desire to keep things as normal as possible. We have policies in place for COVID during athletic events. As a school, we have listened to the governor’s statement to stay at 50% capacity. We feel even [Friday] night, our overall capacity was under 50%."

More than one million people have received the first of two doses of a COVID-19 vaccine in Germany, according to the country's public health agency.

As of Saturday, 1,048,160 first doses had been administered nationwide, according to the latest data from the Robert Koch Institute. So far, the European Medicines Agency has approved two COVID-19 vaccines for use in the European Union -- one developed by U.S. pharmaceutical giant Pfizer and its German partner BioNTech, and another developed by American biotechnology company Moderna.

There were 7,141 new cases of COVID-19 confirmed in Germany on Sunday. An additional 214 deaths from the disease were also registered nationwide. That brings the country's cumulative totals to 2,040,659 cases with 46,633 deaths, according to the Robert Koch Institute.

There were 174,513 new cases of COVID-19 confirmed in the United States on Sunday, according to a real-time count kept by Johns Hopkins University.

It's the first time in two weeks that the country has logged under 200,000 newly confirmed infections in a 24-hour reporting period. Sunday's tally is far less than the country's all-time high of 302,506 new cases on Jan. 2, Johns Hopkins data shows.

An additional 1,723 fatalities from COVID-19 were registered nationwide on Sunday, down from a peak of 4,462 new deaths on Jan. 12, according to Johns Hopkins data.

COVID-19 data may be skewed due to possible lags in reporting over the holiday weekend and earlier holidays.

A total of 23,936,772 people in the U.S. have been diagnosed with COVID-19 since the pandemic began, and at least 397,600 have died, according to Johns Hopkins data. The cases include people from all 50 U.S. states, Washington, D.C., and other U.S. territories as well as repatriated citizens.

Much of the country was under lockdown by the end of March as the first wave of pandemic hit. By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country's cases then hovered around 20,000 for a couple of weeks before shooting back up over the summer.

The numbers lingered around 40,000 to 50,000 from mid-August through early October before surging again to record levels, crossing 100,000 for the first time on Nov. 4, then reaching 200,000 on Nov. 27 before topping 300,000 on Jan. 2.

California's top epidemiologist has recommended pausing the administration of COVID-19 vaccines from Moderna's lot 041L20A due to "possible allergic reactions" that are under investigation.

"A higher-than-usual number of possible allergic reactions were reported with a specific lot of Moderna vaccine administered at one community vaccination clinic," Dr. Erica Pan, state epidemiologist for the California Department of Public Health, said in a statement late Sunday night. "Fewer than 10 individuals required medical attention over the span of 24 hours. Out of an extreme abundance of caution and also recognizing the extremely limited supply of vaccine, we are recommending that providers use other available vaccine inventory and pause the administration of vaccines from Moderna Lot 041L20A until the investigation by the CDC, FDA, Moderna and the state is complete."

The California Department of Health said all of the affected individuals appeared to be experiencing "a possible severe allergic reaction during the standard observation period," which the U.S. Centers for Disease Control and Prevention says some people have experienced when receiving a COVID-19 vaccine.

More than 330,000 doses from that specific lot have been distributed to 287 providers across the state, with the shipments arriving between Jan. 5 and 12, according to the California Department of Public Health, which said it has not been notified of any other cluster or individual events related to this lot.

When asked for comment, a spokesperson for Moderna told ABC News: "Moderna acknowledges receiving a report from the California Department of Public Health (CDPH) that a number of individuals at one vaccination center in San Diego were treated for possible allergic reactions after vaccination from one lot of Moderna’s COVID-19 Vaccine. The company is fully cooperating with CDPH in investigating these reported adverse events. Consistent with the statement from CDPH, at this point Moderna is unaware of comparable adverse events from other vaccination centers which may have administered vaccines from the same lot."

ABC News' Sony Salzman contributed to this report.